Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

8.3K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.3K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

65
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
65

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evidence of Spin-Interference Effects in Exclusive J/ψ→e^{+}e^{-} Photoproduction in Ultraperipheral Heavy-Ion Collisions.

Physical review letters·2026
Same author

First Observation of Deuteron-Λ Correlations at RHIC.

Physical review letters·2026
Same author

Observation of Charmonium Sequential Suppression in Heavy-Ion Collisions at the Relativistic Heavy Ion Collider.

Physical review letters·2026
Same author

Energy Independence of the Collins Asymmetry in p^{↑}p Collisions.

Physical review letters·2026
Same author

Precision Measurement of Net-Proton-Number Fluctuations in Au+Au Collisions at RHIC.

Physical review letters·2025
Same author

From traditional Chinese medicine to molecular oncology - pleiotropic effects of tauroursodeoxycholic acid.

Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti·2025

Related Experiment Video

Updated: Mar 19, 2026

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

14.6K

[Current Possibilities for Predicting Responses to EGFR Blockade in Metastatic Colorectal Cancer].

R Němeček, M Svoboda, O Slabý

    Klinicka Onkologie : Casopis Ceske a Slovenske Onkologicke Spolecnosti
    |June 15, 2016
    PubMed
    Summary

    Identifying patients who will respond to epidermal growth factor receptor (EGFR) blockade is crucial for metastatic colorectal cancer treatment. This review explores predictive markers for EGFR therapy response and their clinical application.

    More Related Videos

    Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
    09:38

    Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

    Published on: August 11, 2017

    9.3K
    A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
    13:34

    A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

    Published on: April 6, 2016

    10.7K

    Related Experiment Videos

    Last Updated: Mar 19, 2026

    Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
    09:29

    Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

    Published on: September 30, 2016

    14.6K
    Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
    09:38

    Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

    Published on: August 11, 2017

    9.3K
    A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
    13:34

    A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

    Published on: April 6, 2016

    10.7K

    Area of Science:

    • Oncology
    • Molecular Biology
    • Clinical Medicine

    Background:

    • Systemic chemotherapy combined with anti-EGFR monoclonal antibodies improves outcomes in metastatic colorectal cancer.
    • Resistance to anti-EGFR therapy can negatively impact progression-free and overall survival.
    • Identifying patient sensitivity or resistance before EGFR blockade is critical for treatment decisions.

    Purpose of the Study:

    • To review current methods for predicting patient response to epidermal growth factor receptor (EGFR) blockade.
    • To discuss the integration of these predictive results into routine clinical practice.

    Main Methods:

    • Review of existing literature on EGFR pathway signaling and resistance mechanisms.
    • Analysis of molecular markers (KRAS, NRAS, BRAF, PIK3CA, PTEN, TP53, EGFR, HER2, epiregulin, amphiregulin, miR-31-3p, miR-31-5p) associated with EGFR blockade response.
    • Evaluation of clinical parameters (tumor shrinkage, response depth, hypomagnesemia) as indicators of treatment benefit.
    • Consideration of next-generation sequencing for combined marker analysis.

    Main Results:

    • Primary resistance to EGFR blockade often stems from constitutive activation of downstream signaling pathways.
    • Only KRAS and NRAS mutation testing is currently standard clinical practice for predicting response.
    • Other molecular markers require further validation for routine use.
    • Clinical parameters like early tumor shrinkage and hypomagnesemia may indicate ongoing benefit from anti-EGFR therapy.

    Conclusions:

    • Accurate prediction of EGFR blockade response in metastatic colorectal cancer is essential.
    • Combining multiple predictive markers, potentially using next-generation sequencing, may enhance diagnostic accuracy.
    • Careful selection and validation of markers are necessary to avoid complicating clinical interpretation.